PMID- 31169742
OWN - NLM
STAT- MEDLINE
DCOM- 20190617
LR  - 20221207
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 23
DP  - 2019 Jun
TI  - Efficacy and safety assessment of S-1-based regimens comparing to intravenous 
      fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A 
      system review and meta-analysis.
PG  - e15999
LID - 10.1097/MD.0000000000015999 [doi]
LID - e15999
AB  - BACKGROUND: We performed the present systematic review and meta-analysis to 
      evaluate the efficacy and safety for S-1-based regimens comparing to intravenous 
      fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma 
      (mCRC). METHODS: Eligible prospective and controlled randomized clinical trials 
      (RCT) were included, of which data were extracted by inclusion criteria and 
      exclusion ones. Odds ratio (OR) and Hazard ratio (HR) of outcomes including 
      objective response rate (ORR), disease control rate (DCR), progressive-free 
      survival (PFS), overall survival (OS), and adverse events (AEs) were explored for 
      the final analysis between the 2 groups. RESULTS: A total of 23 eligible 
      prospective, controlled RCTs including 2269 patients were enrolled for the pooled 
      analysis. With the meta-analysis of available data, the results of the present 
      research showed that there was no statistical difference on short-term efficacy 
      including ORR (HR = 0.85, 95% CI: 0.71-1.01; P = .07) or DCR (HR = 0.88, 95% CI: 
      0.69-1.11; P = .27), as well as long-term efficacy including PFS (HR = 1.00, 95% 
      CI: 0.90-1.11; P = .98) or OS (HR = 0.95, 95% CI: 0.82-1.10; P = .50). In 
      addition, the incidences of AEs including leucopenia, neutropenia, and vomiting 
      were statistically lower in S-1-based regimens comparing to intravenous 
      fluorouracil-based ones, regardless of all grade or high grade (all P <.05). 
      However, there were no significant differences detected among other AEs including 
      anemia, thrombocytopenia, increased alanine aminotransferase concentration, 
      stomatitis, anorexia, diarrhea, hand-foot syndrome (HFS), or sensory neuropathy 
      among the 2 groups (all P >.05). CONCLUSIONS: The present meta-analysis revealed 
      that S-1-based regimens might be associated with comparable efficacy, as well as 
      lower risk of leucopenia, neutropenia, and vomiting at all/high grade comparing 
      to intravenous fluorouracil-based ones in Asian patients with mCRC.
FAU - Chen, Jianxin
AU  - Chen J
AD  - Department of Medical Oncology.
FAU - Wang, Junhui
AU  - Wang J
AD  - Department of Radiation Oncology, Quzhou People's Hospital, Quzhou, Zhejiang, 
      China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Pyrimidines)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Administration, Intravenous
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Asian People/statistics & numerical data
MH  - Carcinoma/*drug therapy/pathology
MH  - Colorectal Neoplasms/*drug therapy/pathology
MH  - Female
MH  - Fluorouracil/*administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Odds Ratio
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Pyrimidines/*administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC6571363
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/06/07 06:00
MHDA- 2019/06/18 06:00
PMCR- 2019/06/07
CRDT- 2019/06/07 06:00
PHST- 2019/06/07 06:00 [entrez]
PHST- 2019/06/07 06:00 [pubmed]
PHST- 2019/06/18 06:00 [medline]
PHST- 2019/06/07 00:00 [pmc-release]
AID - 00005792-201906070-00076 [pii]
AID - MD-D-18-09251 [pii]
AID - 10.1097/MD.0000000000015999 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Jun;98(23):e15999. doi: 10.1097/MD.0000000000015999.